Lead Product(s): Evolocumab
Therapeutic Area: Cardiology/Vascular Diseases
Highest Development Status: Approved Product Type: Large molecule
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition January 23, 2020
Under the acquisition, Amgen Astellas BioPharma will change its name to Amgen K.K., and simultaneously relocate its Headquarters to Tokyo Midtown.